CTOs on the Move

Enveric Biosciences

www.enveric.com

 
Enveric Biosciences is a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of cancer treatments. Enveric Biosciences has set out with the goal of rigorously testing natural compounds, starting with cannabinoids, to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.enveric.com
  • 4851 Tamiami Trail N Suite 200
    Naples, FL USA 34103
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Enveric Biosciences raised $10M on 01/12/2021
Enveric Biosciences raised $12.8M on 02/09/2021

Similar Companies

Regernon Pharmaceuticals

Regernon Pharmaceuticals Inc. is a Tarrytown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innodia

Innodia Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avadim Health

Avadim Health is a life sciences company that offers advanced, safe solutions in everything from immune health to neuromuscular care. They are committed to helping those in need benefit from their products and have a strong pipeline across a broad rang...

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

Canvas Health

Dedicated to bringing hope, healing and recovery to children, adolescents, adults and families struggling with mental health, chemical health and abuse.